Company news
Adaptive Biotechnologies Corporation news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
January 6, 2025
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 1, 2025
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
December 6, 2024
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
December 2, 2024
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
November 6, 2024
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
November 6, 2024
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
October 8, 2024
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
August 28, 2024
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
July 31, 2024
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
July 10, 2024
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 30, 2024
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
May 6, 2024
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
April 16, 2024
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
April 1, 2024
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
March 26, 2024
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
February 21, 2024
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
February 13, 2024
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
January 28, 2024
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 26, 2023
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 8, 2023
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
December 4, 2023
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 6, 2023
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
November 1, 2023
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 12, 2023
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
August 1, 2023
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
July 9, 2023
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 1, 2023
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
May 23, 2023
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 11, 2023
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
May 8, 2023
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
May 2, 2023
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
April 24, 2023
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 11, 2023
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
April 5, 2023
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
February 26, 2023
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
February 13, 2023
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
January 22, 2023
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 26, 2022
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
December 9, 2022
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
December 4, 2022
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
November 30, 2022
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
November 20, 2022
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
November 2, 2022
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
October 10, 2022
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
October 4, 2022
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
September 11, 2022
Calls
The 5 newest of 26 calls. Every call is listed under its year.
- Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2026 Earnings Call
Jul 29, 2026
Transcript - Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2026 Earnings Call
May 5, 2026
Transcript - Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2025 Earnings Call
Feb 6, 2026
Transcript - Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2025 Earnings Call
Nov 5, 2025
Transcript - Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2025 Earnings Call
Aug 5, 2025
Transcript
Decks
The 5 newest of 32 decks. Every deck is listed under its year.
- Q1 2026 Earnings Presentation
Earnings · 31 slides · May 5, 2026
- Q4 2025 Earnings Presentation
Earnings · 15 slides · Feb 5, 2026
- J.P. Morgan Healthcare Conference 2026
Conference · 24 slides · Jan 12, 2026
- Q1 2026 Earnings Presentation
Earnings · 11 slides · 2026
- Q2 2026 Earnings Presentation
Earnings · 13 slides · 2026